Loading viewer...
investor_presentation
Format: PDF investor_presentation
Insmed is a biopharmaceutical company focused on the development and commercialization of ARIKAYCE for nontuberculous mycobacteria (NTM) lung disease. The presentation outlines the company's approved product ARIKAYCE and pipeline candidates including brensocatib and TPIP, along with associated regulatory, commercial and financial risks.
investor_presentation
46 Pages
investor_presentation
28 Pages
Imperial Holdings
investor_presentation
Entergy Corporation
Edgewater Wireless Systems 2023 Investor Presentation
investor_presentationinvestor_presentation
20 Pages
Edgewater Wireless Systems Inc.
investor_presentation
Groupon
Tri-State Generation 2022 Investor Presentation
investor_presentationinvestor_presentation
22 Pages
Tri-State Generation and Transmission Association, Inc.